Melissa Skupin, MD
Allergy & Immunology · Florence, KYNPI 1003115502
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,450 of the $12,219 with a category attached, or 69.2%. 32 manufacturers reported payments, led by Novartis at 36.4% of the total. Reporting peaked in 2024 at $5,137 and has fallen 51.7% since, to $2,483 in 2025.
Across 379 payments — averaging $32.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- GSK$2K
- Sanofi$2K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$471
- Pfizer$297
- plus $2K from 26 others
What the payments were for
- Consulting fees$3,75031%
- Food & beverage$8,45069%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $4,452 |
| GSK | 121 | $1,920 |
| Sanofi | 84 | $1,731 |
| AstraZeneca | 38 | $1,558 |
| Regeneron Healthcare Solutions, Inc. | 18 | $471 |
| Pfizer | 21 | $297 |
| Grifols USA, LLC | 4 | $262 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $260 |
| Amgen | 4 | $228 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $160 |
| Optinose US, Inc. | 4 | $150 |
| Biocryst US Sales Co., LLC | 2 | $106 |
| Alk-abello, Inc | 3 | $70 |
| Genentech USA, Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 4 | $54 |
| Pharming Healthcare, Inc. | 2 | $50 |
| Paratek Pharmaceuticals, Inc. | 2 | $48 |
| Verona Pharma, Inc. | 2 | $40 |
| Kaleo, Inc. | 2 | $38 |
| CSL Behring | 2 | $36 |
| Hospira, Inc. | 1 | $34 |
| Galderma Laboratories, L.p. | 2 | $31 |
| USWM, LLC | 1 | $28 |
| Incyte Corporation | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Covis Pharma GmbH | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
| LEO Pharma Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $11 |
| Boehringer Ingelheim | 1 | $11 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$587
- TEZSPIRE$371
- FASENRA$356
- DUPIXENT$243
- ONGLYZA$131
- AIRSUPRA$131
- BREZTRI$125
- Prolastin-C Liquid$125
- BREZTRI AEROSPHERE$120
How this compares
$12,219 in reported general payments places this provider in the 65th percentile of 66 allergy & immunology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 31 | $117,403 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $114,610 |
| Dupixent PenDupilumab | 14 | $52,389 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $22,029 |
| Advair HfaFluticasone Propion/Salmeterol | 49 | $16,739 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $15,465 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,685 |
| Epinephrine | 64 | $11,522 |
| Arnuity ElliptaFluticasone Furoate | 31 | $6,411 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $4,759 |
| Azelastine Hcl | 146 | $4,470 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,471 |
| Fluticasone Propionate | 141 | $1,434 |
| Ipratropium Bromide | 44 | $1,287 |
| Montelukast Sodium | 175 | $1,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $36 | $114,61013 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,920 | $35,56174 claims |
| AstraZenecaBreztri Aerosphere | $1,558 | $22,02928 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $11,52264 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 66 allergy & immunology providers in Kentucky.
Other allergy & immunology in Florence
- Hans OttoFlorence$381K
- Amy CastilanoFlorence$16K
- Lee CloreOwensboro$841K
- James SublettLouisville$588K
- Stephen PollardLouisville$301K
- Douglas LotzLouisville$199K
- James SublettLouisville$194K
- Timothy FranxmanLouisville$162K
- Jeremy JonesLouisville$149K
- Rajiv AroraLexington$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.